Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Zoetis    ZTS

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Zoetis Inc : APOQUEL® (oclacitinib tablet) Now Available to Treat ‘Itchy’ Dogs

share with twitter share with LinkedIn share with facebook
share via e-mail
01/20/2014 | 06:25pm CEST

FLORHAM PARK, N.J. - Jan. 20, 2014 - Zoetis Inc. today announced that APOQUEL® (oclacitinib tablet) is now available to veterinarians in the United States for the control of pruritus, or itching, associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. With APOQUEL, veterinarians now have a first-in-class treatment choice that targets the itch of allergic skin conditions at its source. Canine itching is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition where APOQUEL would be indicated.

"When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. After gaining five years of experience with APOQUEL through my involvement in clinical trials, I've learned firsthand the difference this treatment can make to a dog and its owners in stopping the itch, but without many of the side effects that are common with steroids," said Thomas Lewis II, DVM, DACVD, practicing veterinary dermatologist at Dermatology for Animals in Gilbert, Ariz. He noted this has been the case even for those dogs that failed to respond to conventional therapies.

"Pet owners who complained that their dogs would wake them up in the middle of the night due to intense itch have told me that after treatment with APOQUEL, the household can sleep more peacefully," Dr. Lewis said. "In my 28 years of practice, this is the most exciting new treatment for the management of itch associated with allergic and atopic dermatitis in dogs, which can often be a challenging and complex condition to treat."

APOQUEL was approved by the U.S. Food and Drug Administration in May 2013 and is the first and only Janus kinase (JAK) inhibitor approved for veterinary use. Its novel mode of action specifically targets and inhibits the cytokines involved in itch and inflammation with minimal activity against cytokines involved in hematopoiesis or innate immune function. Clinical studies have shown that APOQUEL provides rapid relief from itching and improves inflammation in dogs that suffer from allergies, without many of the side effects commonly associated with steroids. In a trial of dogs with allergic dermatitis, APOQUEL produced rapid onset of efficacy within 24 hours. In a trial of dogs with atopic dermatitis, dogs treated with APOQUEL experienced a significant and long-term reduction in itch and inflammation at day 28 of the study. In cases where APOQUEL treatment was continued, success rates remained constant through day 112.

"Zoetis is committed to providing treatments for conditions that affect the lives of pets and their owners who care for them," said Mike McFarland, DVM, DABVP, Group Director, Companion Animal Veterinary Operations at Zoetis. "APOQUEL is just one example that shows how we are continuing to invest in innovative new approaches that help veterinarians address real-world conditions, such as allergic and atopic dermatitis."

For more information, please visit www.apoquel.com.

Important Safety Information

APOQUEL® should not be used in dogs less than 12 months of age or in dogs with serious infections. APOQUEL may increase the susceptibility to infection and demodicosis and may exacerbate neoplastic conditions. APOQUEL has not been evaluated in combination with systemic immunosuppressive agents such as glucocorticoids or cyclosporine. APOQUEL should not be used in breeding dogs, or pregnant or lactating dogs. The most common side effects seen in dogs administered APOQUEL were vomiting and diarrhea. APOQUEL has been safely used in conjunction with other common medications including antibiotics and parasiticides and with vaccinations. For Full Prescribing Information visit www.apoquel.com/Apoquel_PI.

About Zoetis

Zoetis (z

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ZOETIS
06/14ZOETIS : to Participate in the William Blair 2018 Growth Stock Conference
06/14REGENERON PHARMACEUTICALS : and Zoetis Announce Collaboration to Research Antibo..
06/09ZOETIS : ZTS) Holder Brown Advisory INC Has Trimmed Its Stake as Stock Rose
06/07ZOETIS' : Trademark Application for "FLU DETECT" Filed
06/07REGENERON PHARMACEUTICALS : collaborates with Zoetis to research antibody therap..
06/07REGENERON PHARMACEUTICALS : and Zoetis Announce Collaboration to Research Antibo..
06/06ZOETIS : to Participate in the William Blair 2018 Growth Stock Conference
06/06ZOETIS : Regeneron and Zoetis Announce Collaboration to Research Antibody Therap..
06/06Monteverde & Associates PC Announces An Investigation Of Abaxis, Inc. - ABAX
06/01ZOETIS : Named a High Quality Workplace in China
More news
News from SeekingAlpha
06/11YOUR DAILY PHARMA SCOOP : Scynexis Moves Up, Proteostasis Disappoints Investors,.. 
06/06Zoetis teams up with Regeneron to discover new vet treatments 
05/25Abaxis May Not Receive A New Offer 
05/18HESKA : Pets Are People Too 
05/16Zoetis (ZTS) Investor Presentation - Slideshow 
Financials ($)
Sales 2018 5 743 M
EBIT 2018 2 079 M
Net income 2018 1 458 M
Debt 2018 2 927 M
Yield 2018 0,55%
P/E ratio 2018 30,03
P/E ratio 2019 26,51
EV / Sales 2018 8,02x
EV / Sales 2019 7,39x
Capitalization 43 161 M
Duration : Period :
Zoetis Technical Analysis Chart | ZTS | US98978V1035 | 4-Traders
Technical analysis trends ZOETIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 87,7 $
Spread / Average Target -1,7%
EPS Revisions
Juan Ramón Alaix Chief Executive Officer & Director
Mike B. McCallister Non-Executive Chairman
Kristin C. Peck Executive Vice President & President-US Operations
Glenn C. David Chief Financial Officer & Executive Vice President
Catherine Ann Knupp Executive VP, President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ZOETIS23.82%43 161
VIRBAC-0.89%1 202